Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 4/20 | 0.37 |
| ▸ | PPARA | Q07869 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2221549 | 0.90 | PPARG (0.39) | PPARGPPARASMN1; SMN2NPSR1TP53 | |
| SCHEMBL2222766 | 0.89 | PPARG (0.36) | SCN9APPARGPPARASMN1; SMN2ACACB | |
| SCHEMBL2223258 | 0.88 | PPARG (0.36) | PPARGPPARASMN1; SMN2NPSR1TP53 | |
| SCHEMBL2221558 | 0.86 | PPARG (0.36) | SCN9APPARGPPARASMN1; SMN2ACACB | |
| SCHEMBL2224597 | 0.86 | PPARG (0.33) | PPARGPPARASMN1; SMN2ACACBTSHR | |
| SCHEMBL3740890 | 0.85 | SCN9A (0.39) | SCN9ASMN1; SMN2NPSR1TP53MAPT | |
| SCHEMBL2221495 | 0.83 | LMNA (0.41) | SCN9APPARGPPARASMN1; SMN2NPSR1 | |
| SCHEMBL2221406 | 0.80 | SMN1; SMN2 (0.54) | PPARGPPARASMN1; SMN2 | |
| SCHEMBL3728868 | 0.79 | SMN1; SMN2 (0.32) | SCN9ASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL13583861 | 0.79 | PPARG (0.36) | SCN9APPARGPPARASMN1; SMN2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283216-A1 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY | 2012-11-08 | — | — | US | disclosed |
| EP-2516385-A2 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. du Pont de Nemours and Company (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011087837-A9 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011087837-A2 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283216-A1 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | CBR3, CBR1, Q6ZSR9 | SCN9A 105/4885PPARG 3476/4885PPARA 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.